Previous 10 | Next 10 |
2024-04-17 07:40:30 ET More on Sage Therapeutics SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call Transcript Sage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Sizing Up Sage Therapeutics Sage Therapeutics GAAP EPS of -$0.55 beats by $...
- In the Phase 2 PRECEDENT Study, dalzanemdor (SAGE-718) did not show statistically significant differences versus placebo on the primary endpoint in patients with mild cognitive impairment in Parkinson’s disease - Dalzanemdor (SAGE-718) was generally well-tolerated and there...
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET to review first quarter 2024 financial results and discuss recent business u...
2024-04-04 13:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-15 10:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in March: TD Cowen 44 th Annual Health Care Conference (Boston, ...
2024-02-15 13:15:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for SAGE on February 15, 2024 12:59PM ET. The previous analyst recommendation was Sector Perform. SAGE was trading at $25.645 at issue of the analyst recommendation. The overall analyst conse...
2024-02-14 13:00:04 ET SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Conference Call February 14, 2024, 8:00 a.m. ET Company Participants Barry Greene - President, CEO & Director Kimi Iguchi - CFO & Treasurer Laura Gault - Chief Medical Officer Chri...
2024-02-14 06:33:52 ET More on Sage Therapeutics Sizing Up Sage Therapeutics Biogen, Sage launch depression therapy in the U.S. Seeking Alpha’s Quant Rating on Sage Therapeutics Historical earnings data for Sage Therapeutics Financial informati...
ZURZUVAE™ (zuranolone), the first-and-only oral treatment indicated for adults with postpartum depression (PPD), became commercially available mid-December; Sage achieved $0.8 million in collaboration revenue as of December 31, 2023, 50% of the net revenues Biogen reports for ZURZUVAE ...
News, Short Squeeze, Breakout and More Instantly...
Sage Therapeutics Inc. Company Name:
SAGE Stock Symbol:
NASDAQ Market:
Sage Therapeutics Inc. Website:
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
Achieved $6.2 million in ZURZUVAE™ (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues reported by Biogen Encouraging initial demand for ZURZUVAE; More than 700 prescriptions shipped and delivered in the first quarter of 2024 ...
2024-04-24 09:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...